{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T02:54:21Z","timestamp":1783652061341,"version":"3.55.0"},"reference-count":63,"publisher":"Korean Association of Internal Medicine","issue":"3","license":[{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":["kjim.org"],"crossmark-restriction":true},"short-container-title":["Korean J Intern Med"],"published-print":{"date-parts":[[2023,5,1]]},"abstract":"<jats:p>As a genetic disease, there has been a long-standing effort to identify therapeutic options for autosomal dominant polycystic kidney disease (ADPKD). Following the development of tolvaptan, a vasopressin 2 receptor antagonist, the treatment strategy for ADPKD patients with rapid disease progression has been changed with a disease-targeted approach. Tolvaptan showed significant efficacy in preserving kidney function and reducing the total kidney volume (TKV) growth rate. These effects were especially pronounced in patients with more severe clinical phenotypes, such as higher TKV and rapidly declining kidney function. Despite the therapeutic effects of tolvaptan, aquaretic symptoms are unavoidable side effects related to the mechanism of the drug and are also directly related to the quality of life. A shared decision-making process could be a valuable strategy for reducing the incidence of side effects and improving medication adherence. Herein, we aimed to review overall clinical trials for applying tolvaptan and suggest important factors during the shared decision-making process.<\/jats:p>","DOI":"10.3904\/kjim.2022.376","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T06:38:26Z","timestamp":1682318306000},"page":"322-331","update-policy":"https:\/\/doi.org\/10.3904\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Recent updates in therapeutic approach using tolvaptan for autosomal dominant polycystic kidney disease"],"prefix":"10.3904","volume":"38","author":[{"given":"Yaerim","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7561-6534","authenticated-orcid":true,"given":"Seungyeup","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2270","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2021.176"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.07.037"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-007-2888-2_46"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/ncpneph0070"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2015.39"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfu050"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2022.174"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.04560510"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1421"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00243.2011"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1710030"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1205511"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.23876\/j.krcp.21.309"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2006080835"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2009.214"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.23876\/j.krcp.21.261"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.23876\/j.krcp.22.016"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.03.004"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfx043"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-015-1086-2"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2021.05.037"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2174\/1386207322666191203092715"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.987092"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2018060590"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-019-1290-5"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2001.00985.x"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2016.08.028"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/s0272-6386(12)80922-x"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.03100608"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.11.027"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.2147\/dhps.s338050"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2017.07.004"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2019.11.008"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.10250620"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.04.053"},{"key":"ref36","first-page":"354","volume-title":"Determinants of urine volume in ADPKD patients using the vasopressin V2 receptor antagonist tolvaptan","author":"Kramers","year":"2019"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.23876\/j.krcp.21.800"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2021.197"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-018-0957-7"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1097\/fjc.0b013e318074f934"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-015-0327-3"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2019.09.002"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfv456"},{"key":"ref44","first-page":"825","volume-title":"An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease Inte","author":"M\u00fcller","year":"2022"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.3390\/jcm3041276"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.06300615"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.23876\/j.krcp.20.220"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2020.340"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-018-0545-8"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2021.11.034"},{"key":"ref51","volume-title":""},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-015-1219-7"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-021-02097-6"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2022.08.012"},{"key":"ref55","first-page":"248","volume-title":"Urine and plasma osmolality in patients with autosomal dominant polycystic kidney disease: reliable indicators of vasopressin activity and disease prognosis?","author":"Casteleijn","year":"2015"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2016.135"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1042\/bst0070861"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.3.14.2480260"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1016\/s0272-6386(97)90496-0"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1126\/science.1850553"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1520-6408(1999)24:3\/4<309::aid-dvg14>3.0.co;2-5"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1038\/nm935"},{"key":"ref63","first-page":"2499","volume-title":"Tolvaptan in autosomal dominant polycystic kidney disease: three years\u2019 experience","author":"Higashihara","year":"2011"}],"container-title":["The Korean Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.kjim.org\/upload\/kjim-2022-376.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.kjim.org\/journal\/view.php?doi=10.3904\/kjim.2022.376","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.kjim.org\/upload\/kjim-2022-376.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T04:46:42Z","timestamp":1683607602000},"score":1,"resource":{"primary":{"URL":"http:\/\/kjim.org\/journal\/view.php?doi=10.3904\/kjim.2022.376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,1]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"URL":"https:\/\/doi.org\/10.3904\/kjim.2022.376","relation":{},"ISSN":["1226-3303","2005-6648"],"issn-type":[{"value":"1226-3303","type":"print"},{"value":"2005-6648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,1]]},"assertion":[{"value":"2022-12-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-25","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-01","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}